About this trial
Nosebleeds are very common, occurring in 60% of the population; in some patients, nosebleeds are a life-threatening emergency. To stop a nosebleed in the emergency department, doctors usually have to burn the nose (called cauterization) or insert pledgets (called nasal packing) into the nose to apply direct pressure to the bleeding site. Nasal packing can cause pain and discomfort at the time it is inserted in the nose and again when it is removed. In rare cases it can cause a range of complications: minor complications include scar bands in the nose, but serious complications of nasal packing have also occurred, including death. Nasal packing can also present risks to doctors, such as the risk of contracting airborne and bloodborne infections, like COVID-19 and HIV.
Tranexamic acid in pill form or given directly into a vein is a medication that is currently used for nosebleeds. This study looks to evaluate if tranexamic acid in powder form sprayed directly in the nose can be used as an alternative to cauterization or nasal packing for the treatment of nosebleeds.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Capable of giving informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Adults 18 years or older
Male or female
Disqualifiers
Prior sinonasal surgery within the preceding 1 month.
Patients who required medical treatment for epistaxis in the preceding 30 days.
Septum perforation.
Known history of bleeding disorders, including thrombocytopenia, hemophilia, hereditary hemorrhagic telangiectasia, or von Willebrand disease.
Trial design
Single group
Treatments tested in this trial
Tranexamic Acid
DrugTranexamic acid powder intranasally
Treatment groups
Trial outcomes
Primary outcomes
Cessation of epistaxis
Number of participants for whom epistaxis ceased after treatment
Secondary outcomes
Time to cessation of epistaxis
Measured in minutes
Pain of the treatment
Participants' perception of pain will be measured using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain possible).
Total time in the Emergency Department
Measured in minutes
Number of participants who returned to the Emergency Department for treatment of epistaxis
Other outcomes
Age
Anticoagulant and/or antiplatelet medication use
Type of epistaxis
Anterior versus posterior epistaxis
Adverse events and/or patient-reported side effects
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Dr. Anne Conlin
Lead sponsor
Peterborough Regional Health Centre
Sponsor institution
University of Ottawa
Collaborator